Compositions for treating an intestinal inflammatory condition

Abstract

Compositions comprising human Tr1 cells directed to a food antigen from common human diet and methods for treating an intestinal inflammatory condition.

1 . A composition comprising at least one human Tr1 cell population directed against a food antigen from common human diet. 
     
     
         2 . The composition according to  claim 1  comprising at least one human Tr1 cell population directed against a food antigen from common human diet in combination with one or more pharmaceutically acceptable carrier. 
     
     
         3 . The medicament or pharmaceutical composition according to  claim 1 , wherein said human Tr1 cell population is a human Tr1 clone population. 
     
     
         4 . The composition according to  claim 1 , wherein said food antigen from common human diet is selected from the group comprising ovalbumin, casein, beta-lactoglobulin, soya protein, gliadin, peanuts, and fragments, variants and mixtures thereof. 
     
     
         5 . The composition according to  claim 1 , wherein said food antigen from common human diet is ovalbumin, and fragments, variants and mixtures thereof. 
     
     
         6 . A method for treating an intestinal inflammatory condition, comprising administering to a subject in need thereof an effective amount of the composition according to  claim 1 . 
     
     
         7 . The method according to  claim 6 , wherein said intestinal inflammatory condition is an inflammatory bowel disease. 
     
     
         8 . The method according to  claim 7 , wherein said inflammatory bowel disease is Crohn's disease. 
     
     
         9 . The method according to  claim 7 , wherein said inflammatory bowel disease is ulcerative colitis. 
     
     
         10 . The method according to  claim 6 , wherein said intestinal inflammatory condition is an intestinal inflammation linked to food allergy or intolerance. 
     
     
         11 . The method according to  claim 10 , wherein said intestinal inflammation is linked to milk protein allergy. 
     
     
         12 . The method according to  claim 10 , wherein said intestinal inflammation is linked to celiac disease. 
     
     
         13 . The method according to  claim 10 , wherein said intestinal inflammation is linked to hen egg allergy. 
     
     
         14 . The method according to  claim 10 , wherein said intestinal inflammation is linked to peanut allergy 
     
     
         15 . The method according to  claim 6 , wherein the composition to be administered to a subject in need thereof comprises human Tr1 cells autologous to the cells of said subject. 
     
     
         16 . The method according to  claim 6 , wherein 10 4 /kg to 10 9 /kg Tr1 cells are administered to the subject in need thereof. 
     
     
         17 . The method according to  claim 6 , wherein the administration to said subject of an effective amount of the composition is in combination with one or more therapeutic agent used for treating an intestinal inflammatory condition. 
     
     
         18 . The method according to  claim 6 , wherein said subject does not respond adequately to, or is unlikely to respond adequately to, one or more therapeutic agent selected from the group consisting of anti-TNF, natalizumab, anti-IL1, anti-IL-6, anti-IL-12, anti-IL-17 and anti-IL-23; IL-1 receptor antagonist analogs; 5 aminosalicyclic acid and analogs; corticoids, probiotics, methotrexate, azathioprine, 6-mercaptopurine, thalidomide, and leflunomide. 
     
     
         19 . A process for treating an intestinal inflammatory condition in a subject in need thereof, said process comprising the steps of:
 obtaining Tr1 cells directed to a selected food antigen from common human diet, said Tr1 cells being obtained from a blood sample of said subject,   cloning said Tr1 cells directed to a selected a food antigen from common human diet,   further expanding Tr1 clones obtained at the previous step,   re-injecting Tr1 clones thus obtained in said subject, preferably by intravenous route.